Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of NRT6008 Injection in Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases

NCT06278454 is registered in ClinicalTrials.gov with Chengdu New Radiomedicine Technology Co. LTD. as lead sponsor.

NCT NCT06278454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06278454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of NRT6008 Injection in Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases
Lead sponsor
Chengdu New Radiomedicine Technology Co. LTD.
Phase
Phase 1
Overall status
Recruiting
Start date
January 9, 2024
Completion date
June 30, 2028
Enrollment
58 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic cancer, lymph node metastases, unresectable pancreatic cancer